Venetoclax for chronic lymphocytic leukemia in real-world care
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This study looks at how well venetoclax works and how it’s used when people with chronic lymphocytic leukemia (CLL) start the medication in usual, real-life care. It may help doctors better understand what to expect outside of strict study settings.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have chronic lymphocytic leukemia (CLL)
- You are starting venetoclax therapy (or have just started)
- Your venetoclax treatment follows the approved instructions in your local label
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at the long-term effects of taking ibrutinib and venetoclax together for chronic lymphocytic leukemia (CLL). It aims to see how well this treatment works over time and how it affects patients.
This program provides access to venetoclax (a targeted therapy for blood cancers) for patients who have no other treatment options and cannot join a clinical trial. It's designed for those who have run out of standard choices.
This trial tests whether adding oral venetoclax together with an IV antibody called obinutuzumab can control CLL when the disease comes back after a specific prior treatment. It also looks closely at side effects to see what changes in “disease activity” and safety to expect.
This Phase 2 trial tests a combination of three medicines to treat chronic lymphocytic leukemia (CLL) that has not been treated before and where the goal is to achieve very low remaining disease. It may help some people stay in remission longer, but eligibility depends on your age, organ function, and prior treatments.
This trial tests a combination of three drugs—roginolisib, obinutuzumab, and venetoclax—for people with chronic lymphocytic leukemia (CLL) that has come back or stopped responding to previous treatment. The goal is to see if this combination can help control the disease.
This trial tests how well venetoclax (a targeted pill for CLL) works in people whose CLL has come back or hasn’t responded. It also closely tracks early changes in the CLL cells to better understand what happens during treatment.
Hear when a new Chronic Lymphocytic Leukemia (CLL) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.